CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced that the company will be presenting at Obesity 2011, The Obesity Society’s 29th Annual Scientific Meeting, being held Oct. 1-5, 2011 at the Orlando World Center Marriott in Orlando, Fla. Zafgen will present a clinical update on beloranib and Phase 1b study highlights, as well as a poster for fumagillin, a prototype methionine aminopeptidase 2 (MetAP2) inhibitor.
